Pipeline of New Products

Products Currently in Development
Status of Product
Human hepatitis B immunoglobulin (pH4) for intravenous injection
Human fibrinogen
Human Cytomegalovirus Immunoglobulin
Immune Globulin Intravenous (Human), aprylate/Chromatography Purified & 20 nm virus filtration
Human Antithrombin III (concentration)
Prevention of measles and contagious hepatitis. When applied together with antibiotics, its curative effect on certain severe bacteria or virus infection may be improved.
Treatment for lack of fibrinogen and increase human fibrinogen concentration.
Prophylaxis and treatment of CMV infection,especially for the prevention of active virus replication for patients in immunosuppression,such as organ transplantation patients.
Treatment for original immunoglobulin deficiency; secondary immunoglobulin deficiency and auto-immune deficiency diseases
Treatment for (i) hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and (ii) thromboembolism
Application made to the CFDA for official production permit and product certification. Commercial production expected in 2015.
Clinical trial program under CFDA review. Commercial production expected in 2016.
Develop the manufacturing process for the new medicine on an expanded basis in the workshop. Application for clinical trial expected in 2015.
Application in progress for clinical trial. Approval of clinical trials expected in 2015.
Application for clinical trial submitted to CFDA. Approval of clinical trials expected in 2015.

Forward-Looking Statement

This page may include forward-looking statements made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions or otherwise, except as required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in China Biologic’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The contained in this chart was current as of March 16, 2015. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, investors should not rely upon the information as current or accurate after March 16, 2015.

The chart reflects China Biologic’s pipeline of new products as of March 16, 2015.

© 2014 China Biologic Products, Inc. All Rights Reserved.